Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: DR. MEADE who wrote (10796)	1/6/1999 12:35:00 PM
From: DR. MEADE	Respond to of 25711

ATTENTION, yet another APPI PR again today ***** Wednesday January 6, 12:15 pm Eastern Time Company Press Release SOURCE: Advanced Plant Pharmaceuticals, Inc. Advanced Plant Pharmaceuticals, Inc. - APPI - Announces Exclusive Distribution Agreement for Their Patented Cholesterol Lowering Agent Lo-Chol and APPI's New Line of Proprietary Whole Plant Standardized Pharmaceutical Grade Products NEW YORK, Jan. 6 /PRNewswire/ -- Advanced Plant Pharmaceuticals, Inc. (OTC Bulletin Board: APPI - news) announced today that they have signed an agreement with Maxwell Associates, PTYLTD of England. The provisions of the agreement call for the exclusive distribution of Lo-Chol and APPI's new product line of various Pharmaceutical Grade Nutritional products by Maxwell Associates throughout the Country of England. Pursuant to the agreement Maxwell Associates has made an initial purchase order of Lo-Chol and will have an exclusive 3 month trial distribution right to distribute Lo-Chol in the territory of England. Upon the completion of the trial distribution period Maxwell Associates will have the right of first refusal for the distribution of Lo-Chol and APPI's new line of various Pharmaceutical Grade Nutritional products exclusively in England based on minimum purchases and conditions that will be set forth in a new agreement. Barry Clare, Chief Operating Officer for APPI believes that the trial distribution agreement will be the first of many similar distribution agreements to be signed in the near future. Mr. Clare is focused on building significant revenues for APPI through the marketing and distribution of the Company's products. The company expects to announce further agreements in the near future. APPI is a company that develops innovative plant formulations and technology for clinical application. APPI has met FDA nutritional specifications for the marketing of its Lo-Chol in the USA, and has received the first IND from the FDA for a whole plant pharmaceutical which has potential as an immunomodulater in the treatment of patients infected with HIV, the virus that causes AIDS. APPI's Whole Plant Pharmaceutical Grade Process is trade secret and patent pending. Utilization of the APPI process converts a whole plant into the best standardized pharmaceutical grade product. This press release contains forward-looking statements. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. SOURCE: Advanced Plant Pharmaceuticals, Inc. ------------------------------------------------------------------------ More Quotes and News:Advanced Plant Pharmaceuticals Inc (OTC BB:APPI - news)Related News Categories: medical/pharmaceutical ------------------------------------------------------------------------